Christine Papastamelos1, Mitchell Linder2. 1. University of Rochester Medical Center, Internal Medicine, Rochester, NY, USA. Christine_Papastamelos@URMC.Rochester.edu. 2. University of Rochester Medical Center, Obstetrics and Gynecology, Rochester, NY, USA.
Abstract
PURPOSE: To provide a narrative review of anogenital screening for human papillomavirus in solid organ transplant recipients. METHODS: Keyword searches of PubMed and Ovid MEDLINE databases were performed. Keywords included human papillomavirus, malignancy, cervical cancer, Pap smear, solid organ transplant, and immunosuppression. Manual searches were also conducted of other relevant journals and reference lists of primary articles. RESULTS: Forty-one studies, articles, or clinical practice guidelines across 25 years of literature were included. Eligible literature was written in English or offered an English translation. CONCLUSION: Human papillomavirus-related anogenital malignancies disproportionately affect transplant recipients compared to the general population. Evidence-based guidelines for cervical cancer screening and prevention in transplant patients are lacking. Current practice guidelines generally agree on increased Pap screening for transplant recipients compared to the general population. However, recommended screening frequency differs between organizations and amongst medical specialties. Vaccination against HPV remains the most effective strategy to prevent HPV-driven pre-malignant and malignant lesions.
PURPOSE: To provide a narrative review of anogenital screening for human papillomavirus in solid organ transplant recipients. METHODS: Keyword searches of PubMed and Ovid MEDLINE databases were performed. Keywords included human papillomavirus, malignancy, cervical cancer, Pap smear, solid organ transplant, and immunosuppression. Manual searches were also conducted of other relevant journals and reference lists of primary articles. RESULTS: Forty-one studies, articles, or clinical practice guidelines across 25 years of literature were included. Eligible literature was written in English or offered an English translation. CONCLUSION: Human papillomavirus-related anogenital malignancies disproportionately affect transplant recipients compared to the general population. Evidence-based guidelines for cervical cancer screening and prevention in transplant patients are lacking. Current practice guidelines generally agree on increased Pap screening for transplant recipients compared to the general population. However, recommended screening frequency differs between organizations and amongst medical specialties. Vaccination against HPV remains the most effective strategy to prevent HPV-driven pre-malignant and malignant lesions.
Authors: Emiko Petrosky; Joseph A Bocchini; Susan Hariri; Harrell Chesson; C Robinette Curtis; Mona Saraiya; Elizabeth R Unger; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2015-03-27 Impact factor: 17.586